Evolent Health (EVH) PT Lowered to $10 at Truist Securities

Truist Securities analyst Jailendra Singh lowered the price target on Evolent Health (NYSE: EVH) to $10.00 (from $16.00) while maintaining a Buy rating.

The analyst comments "We had a post-quarterly call with EVH management to discuss 3Q25 results, its Q4 guide, thoughts on 2026, cost trends, among other topics. In the text below, we list our questions and the company’s responses. The answers are not verbatim, but we put the company’s answers in their proper context in a give and take format."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Aurora Spine settles patent dispute, secures $600K insider loan
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters